MedTrace Logo

Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major

NCT02761395 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-25

No results posted yet for this study

Summary

1. Evaluate the therapeutic effects, health benefits, and immunological effect of Al-hijamah in children with beta thalassemia major.
2. Evaluate the extent of clinical improvement, reductions in serum iron and ferritin, antioxidant status, in those patients.

Conditions

  • AL-Hijama in Thalassmia Major

Interventions

PROCEDURE

Al-hijamah

* Strict sterilization of selected anatomical sites. * Suction using sterile plastic disposable sucking cups * Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.

DRUG

Deferasirox

20-40 mg/kg/day orally

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mohamed ELshanshory, prof · ethical committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02761395 on ClinicalTrials.gov